Mr. Donald McCaffrey reports

ZENITH EPIGENETICS CORP. COMMENCES OPERATIONS

Zenith Epigenetics Corp., formed as a result of a plan of arrangement involving Resverlogix Corp., RVX Therapeutics Inc. and Zenith pursuant to which Resverlogix spun out Therapeutics to Zenith, commenced operations today as an early-stage research company. Shareholders of Resverlogix now own one new common share of Resverlogix and one common share of Zenith for each common share of Resverlogix held immediately prior to the arrangement becoming effective.

Pursuant to the arrangement, Resverlogix retained its research and development activities related to the development of compounds for applications with indications involving a therapeutic increase in Apolipoprotein A-1, including the clinical program related to RVX-208, a first-in-class small molecule for the treatment of atherosclerosis, and Resverlogix completed the spinoff of all other research and development activities related to its epigenetic platform technology to Zenith. Pursuant to the arrangement, Zenith was also issued royalty preferred shares in the capital of Resverlogix, which will provide Zenith with a dividend equal to 6 to 12 per cent of net Apo revenue as described in the information circular of Resverlogix dated April 29, 2013. As part of the arrangement, Resverlogix also transferred to Zenith all of the indebtedness of Therapeutics owing to Resverlogix, as well as $10-million in cash to provide for the initial capitalization of Zenith.

Management and directors

The management team of Zenith will be led by the management team of Resverlogix, including Donald McCaffrey as president and chief executive officer, Brad Cann as chief financial officer, Kenneth Lebioda as senior vice-president, business and corporate development, Dr. Norman Wong as chief scientific officer and chairman of the scientific advisory board, Dr. Jan Johansson as senior VP, medical affairs, Dr. Gregory Wagner as senior VP, research and development, and Dr. Allan Gordon as senior VP, clinical development.

The board of directors of Zenith consists of Dr. Peter Johann, Mr. McCaffrey, Kenneth Zuerblis, Dr. Eldon Smith, Kelly McNeill and Arthur J. Higgins.

We seek Safe Harbor.